Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 5/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14798187 | 1.00 | CYP1A2 (0.45) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL6697015 | 0.98 | TYR (0.45) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL29624354 | 0.90 | CYP1A2 (0.43) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL27974517 | 0.84 | CYP1A2 (0.46) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL4727798 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL44187 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL4726518 | 0.83 | CYP1A2 (0.45) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL1678922 | 0.81 | CYP1A2 (0.44) | CYP1A2SLC1A3TYRGRIA1GRIA2 | |
| SCHEMBL7001068 | 0.81 | SLC7A5 (0.44) | CYP1A2TYRGRIA1GRIA2GRIA3 | |
| SCHEMBL52215 | 0.81 | CYP2C9 (0.47) | CYP1A2SLC1A3GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| CN-107205948-B | Tablets comprising a GLP-1 agonist and an enteric coating | 诺和诺德股份有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-09-14 | — | — | US | claimed |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2021-06-15 | — | — | US | claimed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | claimed |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2020-03-12 | — | — | US | claimed |
| US-10308700-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2019-06-04 | — | — | US | claimed |
| US-10265384-B2 | Tablets comprising GLP-1 agonist and enteric coating | NOVO NORDISK A/S (DK) | 2019-04-23 | — | — | US | claimed |
| EP-3225631-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2019-01-09 | — | — | EP | claimed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | claimed |
| WO-2012062804-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | claimed |
| US-7893017-B2 | Acylation; point mutations; site-directed mutagenesis; hyperglycemia; diabetes | NOVO NORDISK A/S (DK) | 2011-02-22 | — | — | US | claimed |
| EP-1863839-B1 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2010-08-04 | — | — | EP | claimed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | claimed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | claimed |
| EP-1863839-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| EP-1863521-A1 | EXTENDED GLP-1 COMPOUNDS | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | claimed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | CYP1A2 4181/4885SLC1A3 575/4885TYR 4301/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | CYP1A2 3963/4885SLC1A3 821/4885TYR 3956/4885 |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | CYP1A2 1499/4885SLC1A3 254/4885TYR 4713/4885 |
| US-10308700-B2 | GLP-1 derivatives | GLP1R, GIPR, GCG | CYP1A2 3692/4885SLC1A3 658/4885TYR 1381/4885 |
| US-11117947-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | CYP1A2 4081/4885SLC1A3 667/4885TYR 3278/4885 |
| US-10265384-B2 | Tablets comprising GLP-1 agonist and enteric coating | GLP1R, GIPR, SLC10A2 | CYP1A2 1927/4885SLC1A3 194/4885TYR 2088/4885 |
| US-11034746-B2 | Double-acylated GLP-1 derivatives | GLP1R, SLC5A1, IAPP | CYP1A2 4003/4885SLC1A3 663/4885TYR 3278/4885 |
| US-20200079834-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | GLP1R, SLC5A1, IAPP | CYP1A2 4081/4885SLC1A3 667/4885TYR 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.